The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Royalty Pharma
RPRX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$28.79
0.11
0.38%
At Close: -
$28.79
0
0.00%
After Hours: 4:46 PM EDT
15 minutes delayed
Get Report
Comment
Q2 2024 Earnings in 12 days from now on Thu Aug 8th, before the market open
Royalty Pharma (RPRX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Royalty Pharma (NASDAQ:RPRX) Stock
Royalty Pharma Stock (NASDAQ: RPRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, July 11, 2024
Morgan Stanley Maintains Overweight on Royalt...
Benzinga Newsdesk
Wednesday, June 12, 2024
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
Monday, June 03, 2024
Royalty Pharma Prices Offering Of $1.5B Of Se...
Benzinga Newsdesk
UBS Downgrades Royalty Pharma to Neutral, Ann...
Benzinga Newsdesk
Tuesday, May 28, 2024
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Vandana Singh
Royalty Pharma Acquires Interest In Agios Pha...
Benzinga Newsdesk
Thursday, May 23, 2024
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Vandana Singh
Wednesday, May 22, 2024
Cytokinetics And Royalty Pharma Enter Funding...
Benzinga Newsdesk
Thursday, May 09, 2024
Royalty Pharma Beats Q1 Earnings and Revenue Estimates
Zacks
Royalty Pharma To Acquire Royalties And Miles...
Benzinga Newsdesk
Royalty Pharma Sees FY24 Portfolio Receipts O...
Benzinga Newsdesk
Royalty Pharma Q1 Sales $568.00M Miss $663.22...
Benzinga Newsdesk
Thursday, May 02, 2024
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Erica Kollmann
Arrowhead Pharmaceuticals Earns $50M Mileston...
Benzinga Newsdesk
Friday, April 12, 2024
B of A Securities Maintains Buy on Royalty Ph...
Benzinga Newsdesk
Thursday, April 04, 2024
Looking Into Royalty Pharma's Recent Short Interest
Benzinga Insights
Thursday, February 15, 2024
Royalty Pharma Q4 Sales $596.00M Miss $673.65...
Benzinga Newsdesk
Earnings Scheduled For February 15, 2024
Benzinga Insights
Wednesday, February 14, 2024
Royalty Pharma's Earnings: A Preview
Benzinga Insights
Friday, January 19, 2024
CORRECTION: Royalty Pharma Announces Quarterl...
Benzinga Newsdesk
Royalty Pharma Announces Quarterly Dividend I...
Benzinga Newsdesk
Wednesday, January 17, 2024
Watching MSCI Inc.; Spruce Point Capital Mana...
Benzinga Newsdesk
Monday, January 08, 2024
Royalty Pharma Expects To Deliver Portfolio R...
Benzinga Newsdesk
Monday, November 13, 2023
Teva And Royalty Pharma Announce Collaboratio...
Benzinga Newsdesk
Thursday, November 09, 2023
Morgan Stanley Maintains Overweight on Royalt...
Benzinga Newsdesk
Wednesday, November 08, 2023
Royalty Pharma Sees FY23 Adj. Cash Receipts $...
Benzinga Newsdesk
Royalty Pharma Q3 2023 EPS Adj. Cash Receipts...
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights
Tuesday, November 07, 2023
Royalty Pharma's Earnings Outlook
Benzinga Insights
Thursday, October 19, 2023
PTC Therapeutics Announced An Agreement With ...
Benzinga Newsdesk
Wednesday, October 11, 2023
Morgan Stanley Maintains Overweight on Royalt...
Benzinga Newsdesk
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Thursday, September 07, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Tuesday, September 05, 2023
Ascendis Pharma And Royalty Pharma Enter Into $150M Royalty Funding Agreement; Proceeds To Support Continued Development And Commercialization Of Endocrine Rare Disease Products, And General Corporate Purposes
Happy Mohamed
Thursday, August 24, 2023
Royalty Pharma Pens $500M Royalty Agreement W...
Benzinga Newsdesk
Royalty Pharma And Ferring Pharmaceuticals In...
Benzinga Newsdesk
Wednesday, August 09, 2023
Morgan Stanley Maintains Overweight on Royalt...
Benzinga Newsdesk
Tuesday, August 08, 2023
Royalty Pharma Sees FY23 Adjusted Cash Receip...
Benzinga Newsdesk
Royalty Pharma Q2 Adj EPS $0.84 Beats $0.83 E...
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Tuesday, July 11, 2023
Morgan Stanley Reiterates Overweight on Royal...
Benzinga Newsdesk
Thursday, June 29, 2023
Royalty Pharma CEO Trades Company's Stock
Benzinga Insights
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin
Friday, June 16, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Thursday, June 15, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Wednesday, June 14, 2023
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin
Wednesday, June 07, 2023
Royalty Pharma EVP Sold $6.48M In Company Stock
Benzinga Insights
Thursday, May 25, 2023
CEO of Royalty Pharma Makes $4.84M Buy
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
